Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.

被引：0
|
作者：
Martin, NE
Modi, MW
Reddy, KR
机构：
[1] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[2] Univ Miami, Miami, FL 33152 USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
755
引用
收藏
页码：348A / 348A
页数：1
相关论文
共 50 条
  • [1] Pegylated (40KDA) interferon ALFA-2A (Pegasys™) is unaffected by renal impairment.
    Martin, P
    Mitra, S
    Farrington, K
    Martin, NE
    Modi, MW
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
  • [2] Clearance of pegylated (40KDA) interferon alfa-2a (Pegasys™) is primarily hepatic.
    Modi, MW
    Fulton, JS
    Buckmann, DK
    Wright, TL
    Moore, DJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 371A - 371A
  • [3] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [4] The elderly have a comparable exposure and pharmacodynamics of a branched 40KDA peginterferon alfa-2A (Pegasys™).
    Martin, NE
    Sy, S
    Modi, M
    Ho
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1466 - A1466
  • [5] Pegylated (40kDa) interferon alfa-2a (pegasys™) is superior to interferon alfa-2a (roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.
    Heathcote, EJ
    Balart, LA
    Shiffman, ML
    Pockros, PJ
    Lee, SS
    Reddy, KR
    Minuk, YG
    Bain, V
    Sherman, M
    Wright, TL
    Reindollar, RW
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 223A - 223A
  • [6] The pharmacokinetic behavior of pegylated (40kDa) interferon alfa-2a (PEGASYS™) in chronic hepatitis C patients after multiple dosing.
    Modi, MW
    Fried, M
    Reindollar, RW
    Rustgi, VR
    Kenny, R
    Wright, TL
    Gibas, A
    Martin, NE
    [J]. HEPATOLOGY, 2000, 32 (04) : 394A - 394A
  • [7] Pegylated (40kDa) interferon alfa-2A (Pegasys™) in new combination therapies:: A preliminary report of a randomized, multicenter efficacy and safety study.
    Di Bisceglie, AM
    Bernstein, DE
    Rustgi, VR
    Gitlin, N
    Jeffers, LJ
    Simon, D
    Pappas, SC
    Campagna, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 444A - 444A
  • [8] Improved work productivity, safety, and quality of life with pegylated (40KDA) interferon alfa-2a (Pegasys™) therapy in the treatment of chronic hepatitis C.
    Perrillo, RP
    Thuluvath, PJ
    Rothstein, K
    Alam, I
    Palmer, M
    Gordon, S
    Pappas, SC
    Wynohradnyk, L
    [J]. HEPATOLOGY, 2000, 32 (04) : 362A - 362A
  • [9] Superior virologic response in genotype 4 chronic hepatitis C patients treated with pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with standard interferon.
    Sherman, M
    Dusheiko, GM
    Haeussinger, D
    Marinos, G
    Munoz-Espinoza, L
    Salmeron, J
    DePamphilis, J
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [10] Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40KDA) interferon ALFA-2A (PEGASYS™):: A new profile.
    Lee, SS
    Heathcote, EJ
    Reddy, KR
    Zeuzem, S
    Fried, MW
    Wright, TL
    Pockros, PJ
    Haeussinger, D
    Smith, C
    Pawlotsky, JM
    Mondor, CHUH
    Lin, A
    Pappas, SC
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
12345